Pathophysiological role of microRNA-29 in pancreatic cancer stroma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kwon, Jason J ^a   Nabinger, Sarah C ^a   Vega, Zachary ^b   Sahu, Smiti Snigdha ^a,c   Alluri, Ravi K ^a   Abdul Sater, Zahi ^c   Yu, Zhangsheng ^c   Gore, Jesse ^a,c,d   Nalepa, Grzegorz ^a,c   Saxena, Romil ^c   Korc, Murray ^a,c,d   Kota, Janaiah ^a,d  

^a INDIANA UNIVERSITY   (United States)

^b WABASH COLLEGE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MICRORNA; MIRN29 MICRORNA, HUMAN; PROTEIN P21; SMAD3 PROTEIN; SMAD3 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; C57BL MOUSE; CARCINOMA, PANCREATIC DUCTAL; CELL SURVIVAL; CYTOLOGY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; GENETICS; HUMAN; METABOLISM; MOUSE; PANCREAS; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELL; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; PANCREAS; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; PROTO-ONCOGENE PROTEINS P21(RAS); SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84934930548     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11450     Document Type: Article

References (64)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 64, 9-29 (2014).
2. Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74, 2913-2921 (2014).
3. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
4. Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429 (2012).
5. Hwang, R. F. et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68, 918-926 (2008).
6. Xu, Z. et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol 177, 2585-2596 (2010).
7. Vonlaufen, A. et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 68, 2085-2093 (2008).
8. Andersen, D. K. et al. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas 42, 1227-1237 (2013).
9. Amakye, D., Jagani, Z. & Dorsch, M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 19, 1410-1422 (2013).
10. Ozdemir, B. C. et al. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell 25, 719-34 (2014).
11. Rhim, A. D. et al. Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell 25, 735-47 (2014).
12. Sherman, M. H. et al. Vitamin d receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80-93 (2014).
13. Korc, M. Pancreatic cancer-associated stroma production. Am J Surg 194, S84-86 (2007).
14. Friess, H. et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105, 1846-1856 (1993).
15. Friess, H. et al. Enhanced expression of TGF-betas and their receptors in human acute pancreatitis. Ann Surg 227, 95-104 (1998).
16. Apte, M. V. et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut 44, 534-541 (1999).
17. Feig, C. et al. The pancreas cancer microenvironment. Clin Cancer Res 18, 4266-4276 (2012).
18. Bachem, M. G. et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907-921 (2005).
19. Lonardo, E., Frias-Aldeguer, J., Hermann, P. C. & Heeschen, C. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 11, 1282-1290 (2012).
20. Ikenaga, N. et al. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology 139, 1041-1051, 1051 e1041-1048 (2010).
21. Ambros, V. microRNAs: tiny regulators with great potential. Cell 107, 823-826 (2001).
22. Boudreau, R. L. et al. Transcriptome-wide discovery of microRNA binding sites in human brain. Neuron 81, 294-305 (2014).
23. Mendell, J. T. & Olson, E. N. MicroRNAs in stress signaling and human disease. Cell 148, 1172-1187 (2012).
24. Kwiecinski, M. et al. Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab Invest 92, 978-987 (2012).
25. Wang, B. et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 23, 252-265 (2012).
26. Xiao, J. et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther 20, 1251-1260 (2012).
27. Wang, H. et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 14, 369-381 (2008).
28. Kogure, T. et al. Hepatic miR-29ab1 expression modulates chronic hepatic injury. J Cell Mol Med 16, 2647-2654 (2012).
29. Bowen, T., Jenkins, R. H. & Fraser, D. J. MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. J Pathol 229, 274-285 (2013).
30. Vettori, S., Gay, S. & Distler, O. Role of MicroRNAs in Fibrosis. Open Rheumatol J 6, 130-139 (2012).
31. van Rooij, E. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105, 13027-13032 (2008).
32. Jamieson, N. B. et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 18, 534-545 (2012).
33. Chou, J. et al. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 15, 201-213 (2013).
34. Massague, J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 13, 616-630 (2012).
35. Aikawa, T., Gunn, J., Spong, S. M., Klaus, S. J. & Korc, M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 5, 1108-1116 (2006).
36. Bhowmick, N. A. et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848-851 (2004).
37. Karagiannis, G. S. et al. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res 10, 1403-1418 (2012).
38. Almoguera, C. et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554 (1988).
39. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer cell 4, 437-450 (2003).
40. Omary, M. B., Lugea, A., Lowe, A. W. & Pandol, S. J. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest 117, 50-59 (2007).
41. Schussler, M. H., Skoudy, A., Ramaekers, F. & Real, F. X. Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer. Am J Pathol 140, 559-568 (1992).
42. Noetel, A., Kwiecinski, M., Elfimova, N., Huang, J. & Odenthal, M. microRNA are Central Players in Anti- and Profibrotic Gene Regulation during Liver Fibrosis. Front Physiol 3, 49 (2012).
43. Zhou, L. et al. Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts. PloS One 7, e33766 (2012).
44. Qin, W. et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc of Nephrol 22, 1462-1474 (2011).
45. Wang, L. et al. Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol Ther 20, 1222-1233 (2012).
46. Kenny, H. A. et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest 124, 4614-4628 (2014).
47. Fernandez-Garcia, B. et al. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology 64, 512-522 (2014).
48. Schwarz, R. E. et al. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biol Ther 9, 632-639 (2010).
49. Neuzillet, C. et al. Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget 5, 78-94 (2014).
50. Ohlund, D., Franklin, O., Lundberg, E., Lundin, C. & Sund, M. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer 13, 154 (2013).
51. Armstrong, T. et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 10, 7427-7437 (2004).
52. Grzesiak, J. J., Ho, J. C., Moossa, A. R. & Bouvet, M. The integrin-extracellular matrix axis in pancreatic cancer. Pancreas 35, 293-301 (2007).
53. Kota, J. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017 (2009).
54. Esquela-Kerscher, A. et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7, 759-764 (2008).
55. Kumar, M. S. et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 105, 3903-3908 (2008).
56. Chau, B. N. et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 4, 121ra118 (2012).
57. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 368, 1685-1694 (2013).
58. Lammers, P. Mirna Therapuetics is First to Advance MicroRNA into the Clinic for Cancer. www.mirnarx.com (2013) (Date of access:05/15/2015).
59. Xue, W. et al. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci U S A 111, E3553-3561 (2014).
60. Kasinski, A. L. et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene doi: 10.1038/onc.2014.282 (2014).
61. Mathison, A. et al. Pancreatic stellate cell models for transcriptional studies of desmoplasia-associated genes. Pancreatology 10, 505-516 (2010).
62. Sempere, L. F. & Korc, M. A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. Methods Mol Biol 980, 43-59 (2013).
63. Burgess, A. et al. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci U S A 107, 12564-12569 (2010).
64. Mantoni, T. S., Lunardi, S., Al-Assar, O., Masamune, A. & Brunner, T. B. Pancreatic stellate cells radioprotect pancreatic cancer cells through beta1-integrin signaling. Cancer Res 71, 3453-3458 (2011).